|
業務類別
|
Biotechnology |
|
業務概覽
|
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions. |
| 公司地址
| 11682 El Camino Real, Suite 300, San Diego, CA, USA, 92130 |
| 電話號碼
| +1 858 771-9307 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.ars-pharma.com |
| 員工數量
| 163 |
| Mr. Alexander A. Fitzpatrick, J.D. |
Chief Legal Officer and Secretary |
-- |
29/04/2025 |
| Ms. Kathleen D. Scott |
Chief Financial Officer and Principal Accounting Officer |
-- |
09/03/2026 |
| Mr. Justin Chakma |
Chief Business Officer |
-- |
29/04/2025 |
| Mr. Eric Karas |
Chief Commercial Officer |
-- |
29/04/2025 |
| Dr. Sarina Tanimoto, M.B.A.,M.D. |
Chief Medical Officer |
美元 501.70K |
29/04/2025 |
| Mr. Richard E. Lowenthal, M.B.A.,M.S. |
President, Chief Executive Officer and Director |
美元 651.00K |
09/03/2026 |
| Mr. Brian T. Dorsey, M. Sc. |
Chief Operating Officer |
美元 451.00K |
29/04/2025 |
|
|
| Mr. Brenton L. Saunders |
Director |
09/03/2026 |
| Dr. Peter A. Thompson,M.D.,F.A.C.P. |
Independent Director |
09/03/2026 |
| Dr. Peter Kolchinsky, PhD |
Independent Director |
09/03/2026 |
| Dr. Rajeev Dadoo, PhD |
Independent Director |
09/03/2026 |
| Mr. Michael Kelly |
Independent Director |
09/03/2026 |
| Dr. Laura Shawver, PhD |
Director |
09/03/2026 |
| Mr. Saqib Islam, J.D. |
Independent Director |
09/03/2026 |
| Mr. Richard E. Lowenthal, M.B.A.,M.S. |
President, Chief Executive Officer and Director |
09/03/2026 |
| Dr. Pratik Shah, PhD |
Chairman of the Board |
09/03/2026 |
| Mr. Phillip M. Schneider |
Independent Director |
09/03/2026 |
|
|
|
|
